Pharmaceutical businesses are classified as high-risk by payment processors for reasons that extend beyond the products themselves. The regulatory environment surrounding pharmaceutical sales creates compliance obligations for every entity in the payment chain, including the processor. A processor that underwrites pharmaceutical transactions assumes indirect exposure to FDA enforcement actions, DEA scheduling decisions, state pharmacy board regulations, and the evolving legal framework around health-related products sold online. That exposure is what drives the risk classification.
For pharmaceutical merchants, this means that the processing restriction is not a reflection of the individual business's compliance record or chargeback history. It is a category-level decision driven by the acquirer's assessment of the regulatory environment. Pharmaceutical payment processing through 27 Blockchain operates outside this risk assessment framework because the crypto payment infrastructure does not involve card networks or acquiring banks that make category-level processing decisions.
